DISCLOSURE ISSUES IN THE LIFE SCIENCES INDUSTRY

Join us in discussing disclosure considerations for public companies in the life sciences sector. Our speakers will delve into the industry’s intricacies and challenges, with a particular emphasis on the nuances relevant to biotech companies.

TOPICS WILL INCLUDE:

• Background on disclosure obligations
• Materiality standard and caselaw
• Intersection of disclosure obligations and the US Food and Drug Administration
  • Crafting disclosures to comply with FDA standards (overview of FDA promotional and scientific exchange standards, as applied to investor communications)
  • Regulatory strategy and disclosure strategy
  • Common regulatory developments that may have disclosure implications
• Partnerships, licensing arrangements, collaborations, and disclosures